Kathryn L Taylor1, Rebecca Shelby, Edward Gelmann, Colleen McGuire. 1. Cancer Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, 2233 Wisconsin Ave., NW, Ste. 317, Washington, DC 20007, USA. taylorkl@georgetown.edu
Abstract
BACKGROUND: The National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was designed to examine whether annual screening tests for these four tumor sites result in reduced disease-related mortality. We assessed the impact of trial participation on both health-related quality of life (HRQL) and trial adherence. METHODS:Participants (N = 432; 217 in the control arm and 215 in screening arm) were accrued from the Georgetown University PLCO site from May through December 1998. Screening-arm participants were interviewed by telephone at baseline (prescreening), shortly after notification of screening results (short-term follow-up), and 9 months after notification of screening results (intermediate-term follow up). Control-arm participants completed a baseline and 1-year follow-up assessment. Logistic regression analyses were conducted. RESULTS: Participants reported high levels of HRQL and satisfaction with their decision to participate. Screening-arm participants with abnormal screening results had a higher level of intrusive thoughts about cancer than those with all normal results (odds ratio [OR] = 2.9, 95% confidence interval [CI] = 1.3 to 6.3) at the short-term follow-up but not at the intermediate-term follow-up (when abnormal test results were known to be false positive; OR = 1.9, 95% CI = 0.89 to 4.2). Trial adherence was statistically significantly better among participants who had received all normal results in the previous year's screening tests (93.7% versus 78.7%; OR = 3.7, CI = 1.1 to 12.0) than in those who received at least one abnormal result. In the control arm, adherence (defined as returning annual questionnaires) was positively associated with education (OR = 3.4, 95% CI = 1.4 to 8.4) and sex, with women being more likely to return questionnaires than men (OR = 2.1, 95% CI = 1.05 to 4.4). CONCLUSIONS: It is feasible to collect HRQL measures as part of a large cancer screening trial. Prior abnormal screening results were related to short-term HRQL but not to intermediate-term HRQL. Trial adherence was poorer among those who had received previous false-positive results. These results suggest several methods for improving adherence in this and other subgroups.
RCT Entities:
BACKGROUND: The National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was designed to examine whether annual screening tests for these four tumor sites result in reduced disease-related mortality. We assessed the impact of trial participation on both health-related quality of life (HRQL) and trial adherence. METHODS:Participants (N = 432; 217 in the control arm and 215 in screening arm) were accrued from the Georgetown University PLCO site from May through December 1998. Screening-arm participants were interviewed by telephone at baseline (prescreening), shortly after notification of screening results (short-term follow-up), and 9 months after notification of screening results (intermediate-term follow up). Control-arm participants completed a baseline and 1-year follow-up assessment. Logistic regression analyses were conducted. RESULTS:Participants reported high levels of HRQL and satisfaction with their decision to participate. Screening-arm participants with abnormal screening results had a higher level of intrusive thoughts about cancer than those with all normal results (odds ratio [OR] = 2.9, 95% confidence interval [CI] = 1.3 to 6.3) at the short-term follow-up but not at the intermediate-term follow-up (when abnormal test results were known to be false positive; OR = 1.9, 95% CI = 0.89 to 4.2). Trial adherence was statistically significantly better among participants who had received all normal results in the previous year's screening tests (93.7% versus 78.7%; OR = 3.7, CI = 1.1 to 12.0) than in those who received at least one abnormal result. In the control arm, adherence (defined as returning annual questionnaires) was positively associated with education (OR = 3.4, 95% CI = 1.4 to 8.4) and sex, with women being more likely to return questionnaires than men (OR = 2.1, 95% CI = 1.05 to 4.4). CONCLUSIONS: It is feasible to collect HRQL measures as part of a large cancer screening trial. Prior abnormal screening results were related to short-term HRQL but not to intermediate-term HRQL. Trial adherence was poorer among those who had received previous false-positive results. These results suggest several methods for improving adherence in this and other subgroups.
Authors: Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Karen M Kuntz; Jo-Anne O Shepard; Stephen J Swensen; G Scott Gazelle Journal: Radiology Date: 2008-05-05 Impact factor: 11.105
Authors: Ellen R Gritz; Kathryn B Arnold; Carol M Moinpour; Allison M Burton-Chase; Catherine M Tangen; Jeffrey F Probstfield; William A See; Michael M Lieber; Vincent Caggiano; Sarah Moody-Thomas; Connie Szczepanek; Anne Ryan; Susie Carlin; Shannon Hill; Phyllis J Goodman; Rose Mary Padberg; Lori M Minasian; Frank L Meyskens; Ian M Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-15 Impact factor: 4.254
Authors: Renda Soylemez Wiener; Michael K Gould; Steven Woloshin; Lisa M Schwartz; Jack A Clark Journal: Health Expect Date: 2012-12-16 Impact factor: 3.377
Authors: Marc R Freiman; Jack A Clark; Christopher G Slatore; Michael K Gould; Steven Woloshin; Lisa M Schwartz; Renda Soylemez Wiener Journal: J Thorac Oncol Date: 2016-03-07 Impact factor: 15.609
Authors: L Hol; J A Wilschut; M van Ballegooijen; A J van Vuuren; H van der Valk; J C I Y Reijerink; A C M van der Togt; E J Kuipers; J D F Habbema; M E van Leerdam Journal: Br J Cancer Date: 2009-04-07 Impact factor: 7.640
Authors: K A M van den Bergh; M L Essink-Bot; G J J M Borsboom; E Th Scholten; M Prokop; H J de Koning; R J van Klaveren Journal: Br J Cancer Date: 2009-11-24 Impact factor: 7.640